Cargando…
Widely available lysosome targeting agents should be considered as potential therapy for COVID-19
While the coronavirus disease 2019 (COVID-19) pandemic advances, the scientific community continues to struggle in the search for treatments. Several improvements have been made, including discovery of the clinical efficacy of chloroquine (CQ) in patients with COVID-19, but effective treatment proto...
Autores principales: | Homolak, J., Kodvanj, I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V. and International Society of Chemotherapy.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275137/ https://www.ncbi.nlm.nih.gov/pubmed/32522674 http://dx.doi.org/10.1016/j.ijantimicag.2020.106044 |
Ejemplares similares
-
Preliminary analysis of COVID-19 academic information patterns: a call for open science in the times of closed borders
por: Homolak, J., et al.
Publicado: (2020) -
An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19
por: Homolak, Jan, et al.
Publicado: (2021) -
Publishing of COVID-19 preprints in peer-reviewed journals, preprinting trends, public discussion and quality issues
por: Kodvanj, Ivan, et al.
Publicado: (2022) -
Lysosome-targeting agents in cancer therapy
por: Kroemer, Guido, et al.
Publicado: (2017) -
COVID-19 and diabetes management: What should be considered?
por: Ceriello, Antonio, et al.
Publicado: (2020)